Genentech

Genentech Inc., is a biotechnology corporation which became a subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche.

As of November 2014, Genentech employed nearly 12,900 people. In July 2014, Genentech announced its acquisition of Seragon for up to $1.725 billion.

History

The company was founded in 1976 by venture capitalist Robert A. Swanson and biochemist Herbert Boyer. Boyer is considered to be a pioneer in the field of recombinant DNA technology. In 1973, Boyer and his colleague Stanley Norman Cohen demonstrated that restriction enzymes could be used as "scissors" to cut DNA fragments of interest from one source, to be ligated into a similarly cut plasmid vector. While Cohen returned to the laboratory in academia, Swanson contacted Boyer to found the company. Boyer worked with Arthur Riggs and Keiichi Itakura from the Beckman Research Institute, and the group became the first to successfully express a human gene in bacteria when they produced the hormone somatostatin in 1977.David Goeddel and Dennis Kleid were then added to the group, and contributed to its success with synthetic human insulin in 1978.

Podcasts:

PLAYLIST TIME:

Open The Eyes Of My Heart

by: John Tesh

Open the eyes of my heart Lord
Open the eyes of my heart
I want to see you
I want to see you
I want to see you
To see You high and lifted up
Shining in the light of Your glory
Pour out Your power and love
As we sing holy, holy, holy
Holy, holy, holy
Holy, holy, holy
Holy, holy, holy
I want to see you




Latest News for: genentech

Circulating DNA RNA Patent Landscape Report And Forecast 2024-2032: Nantomics, Genentech, And Novartis Are Pivotal ...

MENA FN 14 Mar 2025
(MENAFN - GlobeNewsWire - Nasdaq) Dublin, March 14, 2025 (GLOBE NEWSWIRE) -- The "Circulating DNA RNA Patent Landscape Report and Forecast 2024-2032" report has been added to ... .

FDA Accepts Supplemental Biologics License Application for Genentech’s Gazyva for the Treatment of Lupus Nephritis (Genentech Inc)

Public Technologies 05 Mar 2025
Genentech, a member of the Roche Group (SIX ... In the United States, Gazyva is part of a collaboration between Genentech and Biogen ... Report side effects to Genentech at (888) 835-2555 ... You may also report side effects to Genentech at (888) 835-2555.

FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults

Business Wire 04 Mar 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX.

FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults (Roche Holding AG)

Public Technologies 03 Mar 2025
). The text version of this document is not available ... Disclaimer ... (noodl. 122799435) .

FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults (Genentech Inc)

Public Technologies 03 Mar 2025
Genentech has developed the only two FDA-approved medicines to treat acute ischemic stroke, TNKase and Activase® (alteplase) ... Genentech, a member of the Roche Group (SIX ... They may contact Genentech by calling 1-888-835-2555 ... About Genentech in Stroke.
  • 1
×